Therma Bright Inc.’s Digital Cough Technology (DCT) is being considered for a new chronic cough drug in a U.S.-based clinical trial. The AI-powered platform, developed in collaboration with smart-health company AI4LYF, aims to enhance healthcare decision-making by improving the collection, organization, and presentation of cough and respiratory data.
Therma Bright holds exclusive worldwide licensing rights to market and sell products based on AI4LYF’s DCT. This mobile app enables the recording and collection of cough sounds using a smartphone, with AI-machine learning technology that can detect various respiratory diseases through changes in cough features.
Studies have indicated a correlation between cough severity and disease activity in asthma and other respiratory conditions. Therma Bright’s CEO, Rob Fia, expressed optimism about the potential use of DCT in a U.S. clinical trial for a new chronic cough drug, emphasizing the platform’s ability to facilitate accurate and informed clinical decisions.
The company is actively working on meeting classification and regulatory requirements for its AI digital cough technology as a remote therapeutic monitoring solution, as requested by the U.S. Food and Drug Administration. Therma Bright continues to advance its diagnostic and medical device technologies to address significant medical and healthcare challenges.
Therma Bright Inc. (TSXV:THRM) last traded at $0.085 per share, with notable increases in value over the past week and month. Investors can engage in discussions about the company’s performance on the Therma Bright Bullboard and other stock forums on Stockhouse’s platform.
This information is provided for informational purposes only and should not be construed as investment advice. For complete disclaimer information, please refer to the provided link.
